Clinical Report: Emerging Applications of Antibody Therapies in Lung Cancer
Background
Lung cancer is the leading cause of cancer-related mortality. Antibody therapies, especially ADCs, have emerged as options that combine targeted delivery with cytotoxic effects. Understanding their mechanisms and clinical applications is crucial for advancing lung cancer treatment.
Data Highlights
No specific numerical data is available in the source material.
Key Findings
ADCs represent a significant advancement in lung cancer therapy, combining targeted antigen recognition with cytotoxic payloads.
Recent approvals of ADCs for NSCLC include telisotuzumab vedotin-tllv and datopotamab deruxtecan-dlnk.
ADCs can exploit non-oncogenic cell-surface antigens, allowing for effective treatment of tumors with diverse antigen expression.
Challenges such as antigen diversity and resistance to payloads continue to impact the clinical application of ADCs.
Emerging antibody-based modalities, including bispecific antibodies and immune-stimulating ADCs, are expanding therapeutic options.
Clinical Implications
Clinicians should stay informed about the evolving landscape of antibody therapies.
Conclusion
Antibody therapies, particularly ADCs, are being explored in the treatment of lung cancer.
